Brief: Glycomimetics Reports Financial Results For Fourth Quarter And Year-End 2022
29/03/2023 12:30
March 29 (Reuters) - GlycoMimetics Inc GLYC.O :
* GLYCOMIMETICS REPORTS HIGHLIGHTS AND FINANCIAL RESULTS FOR
FOURTH QUARTER AND YEAR-END 2022
* GLYCOMIMETICS INC SAYS CASH AND CASH EQUIVALENTS EXPECTED
TO
FUND CURRENT OPERATIONS TO YEAR END 2024
* GLYCOMIMETICS INC - QTRLY LOSS PER SHARE $0.19
Source text for Eikon: ID:nBw2X83hHa
Further company coverage: GLYC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Crescent Biopharma
See all newsBrief: Crescent Biopharma - Potential To Initiate First CR-001 Phase 3 Study In Early 2028
Brief: Crescent Biopharma Announces FDA Clearance Of Ind Application For CR-002, A Pd-L1-Targeted Topoisomerase Inhibitor Adc, For The Treatment Of Solid Tumors
Crescent Biopharma posts smaller-than-expected Q2 net loss
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Crescent Biopharma slips on $125 mln share offering